Physician profile
Kelsea Kill
NPI 1508624065
$3,333.60
in general payments reported to CMS, 2019-2025
31 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,667 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,333.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.67 | 2024-2025 | |
| Novo Nordisk INC | $315.14 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $297.67 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $292.84 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $244.04 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $235.48 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $159.08 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Dexcom, INC. | $117.81 | 2024-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $109.99 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Radius Health, INC. | $82.04 | 2024-2025 | Tymlos |
| Exact Sciences Corporation | $80.37 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $77.96 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $70.80 | 2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.01 | 2024-2025 | Jardiance, Synjardy |
| Abiomed | $51.78 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $48.53 | 2024-2025 | NP Thyroid 60 |
| Eisai INC. | $44.44 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.31 | 2024-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $41.82 | 2024-2025 | |
| Tris Pharma INC | $39.00 | 2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $37.74 | 2025 | Sunosi, Auvelity |
| Inspire Medical Systems, INC. | $37.49 | 2025 | Inspire |
| Medtronic, INC. | $35.44 | 2024-2025 | Symplicity G3, Inceptiv |
| Renalytix Ai, INC. | $32.64 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Edwards Lifesciences Corporation | $30.55 | 2025 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $19.91 | 2024 | |
| Vanda Pharmaceuticals INC. | $18.15 | 2025 | Fanapt |
| Esperion Therapeutics, INC. | $16.89 | 2024 | Nexletol |
| Scilex Pharmaceuticals INC. | $15.14 | 2024 | |
| Lundbeck LLC | $14.16 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $13.71 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsea Kill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.